Molecular Innovations Toward Theranostics of Aggressive Prostate Cancer
Abstract
In this project, we propose to develop a new drug delivery vehicle based on dendrimer nanotechnology for personalized medicine. This new class of nanoplatforms contains imaging probe and molecular medicine with a cancer-specific targeting capability which is able to target cancer cells, monitor drug delivery and tumor response to achieve a see and treat strategy as a new concept of molecular medicine. Specifically, One Partner PIs lab will make dendrimers bearing functional handles to conjugate with chelating agents provided by the Initiating PIs lab for PET imaging and therapeutic peptides provided by another Partner PIs lab for the treatment of aggressive prostate cancer. As the continuation of last years work, we have designed and successfully prepared a theranostic small molecule drug conjugate T-SMDC which consists of tumor-specific ligand, PET imaging moiety, and cytotoxic drug. The resulted theranostic small-molecule drug conjugate (T-SMDC) remains the PSMA binding affinity and exhibits PSMA-dependent anti-cancer toxicity. To date, we have developed the radiochemistry procedure to label the T-SMDC with (68)Ga efficiently. We have started evaluating its therapeutic performance along with the concurrent PET imaging in PSMA+ tumor bearing mice.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2015
- Accession Number
- AD1001599
Entities
People
- Xiankai Sun
Organizations
- University of Texas Southwestern Medical Center